New life for proven medicines

Sustained Release makes it easier and safer to treat type II diabetes, prostate and breast cancer, and manage pain.

Sustained Release is the biggest advancement since basic polymer time release formulations were introduced. For the first time, Sustained Release makes it possible to deliver medications consistently and accurately. Patients receive the prescribed amount each day, no spikes at the outset that have to be countered with other drugs. For selected medications a single injection can be designed to last up to a year. Transforming the quality of care for the 21st century and beyond.

Learn More
More Info

Efficient Production

Precise manufacturing reduces production loses from 60% to 5% compared to current technology, and extends the life span of established drugs for our partners.

More Info
More Info

Patented Technology

We've vastly improved how polymers control the delivery of medicines, eliminating the "burst effect" that undermines existing approaches. A single dose using our patented approach can deliver critical medications smoothly up to a year from injection.

More Info
More Info

Customizable Formulations

We've identified three conditions for initial development. Unlike current technology, Sustained Release can deliver a wider range of medicines, even proteins.

More Info

Partnered for success

The technology behind the transformation of chronic care strategies has been developed by our partner Akina, Inc., a leader in the field of polymers and hydrogels for controlled drug delivery. Their patents, and patent pending advancements, improve the patient experience and bring value to the manufacturers. They will lead the work to gain FDA approval of the three medicines Sustained Release is targeting in the first phase.

  • type II diabetes (Bydureon),
  • prostate and breast cancer (luteinizing-hormone releasing hormone agonist)
  • an abuse deterrent pain medication (oxycodone)
More Info


#

The Hydrogel Template Strategy (HTS) developed by Akina produces micro-sized containers made of polymers of PLGA poly(lactic-co-glycolic acid) that are filled with pharmaceutical compounds. The resulting steady, measured drug delivery eliminates the burst effect of current technology, and the need to take other medicines to counter the excess medicine. It also extends the time between injections over a significantly longer period of time, up to one year, than any timed release technology in the marketplace today.

Akina’s founder, Kinam Park, Ph. D., has devoted his career to pharmaceutical innovation. He was recognized by the Controlled Release Society for his service in 2015, and serves as the editor-in-chief of their peer reviewed journal.

Get in Touch
#

Partner with an industry leader

Sustained Release is developing commercialization strategies for the industry leading advancements by Akina in homogeneous nano/microparticles, nanofabrication, hydrotropic polymeric micelles, superporous hydrogels, fast melting tablet formulations, and drug-eluting stents. Working in partnership with drug manufacturers and investors we can offer substantial advantages from collaborative development, the FDA approval process, and the marketing of new drug delivery solutions.

Our investment and industry partners will reap the benefits of the strategy of working with established medicines that treat common chronic conditions. The drugs are not altered in the process, and the use of polymers to time release medicine is an established technology so FDA approvals are anticipated to be accelerated. Improving patient care for Type II diabetes, breast and prostate cancer, and pain management is a high priority, and the shorter time to market will compress the return on investment compared to conventional drug projects. Additional value to our industry partners comes from extending their market advantage for maturing drugs beyond the expiration of their original patents.

Contact us for more information on how you can partner with Sustained Release to improve chronic care options.

Contact Us